# A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

> **NCT00001266** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (—)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** Suramin

## Key facts

- **NCT ID:** NCT00001266
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1990-10
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** 70 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001266, "A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00001266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*